Novel isoprenoyl nanoassembled prodrug for paclitaxel delivery

Bioconjugate Chemistry

Volumn 24, Issue 11, 2013, Pages 1840-1849

  Mura, Simona ^a,b   Zouhiri, Fatima ^a,b   Lerondel, Stephanie ^c   Maksimenko, Andrei ^a,b   Mougin, Julie ^a,b   Gueutin, Claire ^a,b   Brambilla, Davide ^a,b   Caron, Joachim ^a,b   Sliwinski, Eric ^a,b   Lepape, Alain ^c,d   Desmaele, Didier ^a,b   Couvreur, Patrick ^a,b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b UNIV PARIS SUD   (France)

^c CNRS   (France)

^d UNIVERSITÉ DE TOURS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; DRUG DELIVERY; NANOPARTICLES; SURFACE ACTIVE AGENTS; TERPENES;

ANTICANCER ACTIVITIES; BIOCONJUGATES; DRUG MOLECULES; HIGH DRUG LOADINGS; HYDROXYL GROUPS; IN-VIVO; PACLITAXEL; PACLITAXEL DELIVERY; PRODRUGS; SURFACE-ACTIVE AGENTS;

TUMORS;

CREMOPHOR; ISOPRENE; MACROGOL; NANOCARRIER; PACLITAXEL; SQUALENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CARBON NUCLEAR MAGNETIC RESONANCE; CELL GROWTH; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; FEMALE; IC 50; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL LINE; WEIGHT CHANGE; WEIGHT REDUCTION;

ANIMALIA; MURINAE; MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; BUTADIENES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HEMITERPENES; HUMANS; INHIBITORY CONCENTRATION 50; MCF-7 CELLS; MICE; MICE, INBRED BALB C; NANOPARTICLES; NEOPLASMS, EXPERIMENTAL; PACLITAXEL; PENTANES; PRODRUGS; TUMOR CELLS, CULTURED;

EID: 84888621127     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc400210x     Document Type: Article

References (82)

1. Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P., and McPhail, A. T. (1971) Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia J. Am. Chem. Soc. 93, 2325-2327
2. Spencer, C. M. and Faulds, D. (1994) Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer Drugs 48, 794-847
3. Schiff, P. B., Fant, J., and Horwitz, S. B. (1979) Promotion of microtubule assembly in vitro by taxol Nature 277, 665-667
4. Liggins, R. T., Hunter, W. L., and Burt, H. M. (1997) Solid-state characterization of paclitaxel J. Pharm. Sci. 86, 1458-1463
5. Gelderblom, H., Verweij, J., Nooter, K., and Sparreboom, A. (2001) Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation Eur. J. Cancer 37, 1590-1598
6. Lorenz, W., Reimann, H. J., Schmal, A., Dormann, P., Schwarz, B., Neugebauer, E., and Doenicke, A. (1977) Histamine release in dogs by Cremophor E1 and its derivatives: Oxethylated oleic acid is the most effective constituent Agents Actions 7, 63-67
7. Szebeni, J., Muggia, F. M., and Alving, C. R. (1998) Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: An in vitro study J. Natl. Cancer Inst. 90, 300-306
8. ten Tije, A. J., Verweij, J., Loos, W. J., and Sparreboom, A. (2003) Pharmacological effects of formulation vehicles-Implications for cancer chemotherapy Clin. Pharmacokinet. 42, 665-685
9. Wiernik, P. H., Schwartz, E. L., Strauman, J. J., Dutcher, J. P., Lipton, R. B., and Paietta, E. (1987) Phase I clinical and pharmacokinetic study of taxol Cancer Res. 47, 2486-2493
10. Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R., Jr., Van Echo, D. A., Von Hoff, D. D., and Leyland-Jones, B. (1990) Hypersensitivity reactions from taxol J. Clin. Oncol. 8, 1263-1268
11. Knemeyer, I., Wientjes, M. G., and Au, J. L. S. (1999) Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment Cancer Chemother. Pharmacol. 44, 241-248
12. Ng, S. S. W., Figg, W. D., and Sparreboom, A. (2004) Taxane-mediated antiangiogenesis in vitro: Influence of formulation vehicles and binding proteins Cancer Res. 64, 821-824
13. Sparreboom, A., van Zuylen, L., Brouwer, E., Loos, W. J., de Bruijn, P., Gelderblom, H., Pillay, M., Nooter, K., Stoter, G., and Verweij, J. (1999) Cremophor EL-mediated alteration of paclitaxel distribution in human blood: Clinical pharmacokinetic implications Cancer Res. 59, 1454-1457
14. Lundberg, B. B. (1997) A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol) J. Pharm. Pharmacol. 49, 16-21
15. Sharma, A. and Straubinger, R. M. (1994) Novel taxol formulations- preparation and characterization of taxol-containing liposomes Pharm. Res. 11, 889-896
16. Koudelka, Š. and Turánek, J. (2012) Liposomal paclitaxel formulations J. Controlled Release 163, 322-334
17. Alkanonyuksel, H., Ramakrishnan, S., Chai, H. B., and Pezzuto, J. M. (1994) A mixed micellar formulation suitable for the parenteral administration of taxol Pharm. Res. 11, 206-212
18. Lee, S. C., Huh, K. M., Lee, J., Cho, Y. W., Galinsky, R. E., and Park, K. (2007) Hydrotropic polymeric micelles for enhanced paclitaxel solubility: In vitro and in vivo characterization Biomacromolecules 8, 202-208
19. Shuai, X. T., Merdan, T., Schaper, A. K., Xi, F., and Kissel, T. (2004) Core-cross-linked polymeric micelles as paclitaxel carriers Bioconjugate Chem. 15, 441-448
20. Wang, T., Petrenko, V. A., and Torchilin, V. P. (2010) Paclitaxel-loaded polymeric micelles modified with MCF-7 cell-specific phage protein: Enhanced binding to target cancer cells and increased cytotoxicity Mol. Pharmaceutics 7, 1007-1014
21. Jiang, X., Xin, H., Sha, X., Gu, J., Jiang, Y., Law, K., Chen, Y., Chen, L., Wang, X., and Fang, X. (2011) PEGylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel for the treatment of advanced glioma: In vitro and in vivo evaluation Int. J. Pharm. 420, 385-394
22. Koziara, J. M., Lockman, P. R., Allen, D. D., and Mumper, R. J. (2004) Paclitaxel nanoparticles for the potential treatment of brain tumors J. Controlled Release 99, 259-269
23. Yeh, T. K., Lu, Z., Wientjes, M. G., and Au, J. L. S. (2005) Formulating paclitaxel in nanoparticles alters its disposition Pharm. Res. 22, 867-874
24. Letchford, K. and Burt, H. M. (2012) Copolymer micelles and nanospheres with different in vitro stability demonstrate similar paclitaxel pharmacokinetics Mol. Pharm. 9, 248-260
25. Bhardwaj, V., Ankola, D. D., Gupta, S. C., Schneider, M., Lehr, C. M., and Kumar, M. N. (2009) PLGA nanoparticles stabilized with cationic surfactant: Safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat Pharm. Res. 26, 2495-2503
26. Lo, S. T., Stern, S., Clogston, J. D., Zheng, J., Adiseshaiah, P. P., Dobrovolskaia, M., Lim, J., Patri, A. K., Sun, X., and Simanek, E. E. (2010) Biological assessment of triazine dendrimer: Toxicological profiles, solution behavior, biodistribution, drug release and efficacy in a PEGylated, paclitaxel construct Mol. Pharmaceutics 7, 993-1006
27. Ooya, T., Lee, J., and Park, K. (2003) Effects of ethylene glycol-based graft, star-shaped, and dendritic polymers on solubilization and controlled release of paclitaxel J. Controlled Release 93, 121-127
28. Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., and O'Shaughnessy, J. (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer J. Clin. Oncol. 23, 7794-7803
29. Fu, Q., Sun, J., Zhang, W. P., Sui, X. F., Yan, Z. T., and He, Z. G. (2009) Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery Recent Pat. Anti-Cancer 4, 262-272
30. Lee, K. S., Chung, H. C., Im, S. A., Park, Y. H., Kim, C. S., Kim, S. B., Rha, S. Y., Lee, M. Y., and Ro, J. (2008) Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer Breast Cancer Res. Treat. 108, 241-250
31. Deutsch, H. M., Glinski, J. A., Hernandez, M., Haugwitz, R. D., Narayanan, V. L., Suffness, M., and Zalkow, L. H. (1989) Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of taxol with potent antitumor activity J. Med. Chem. 32, 788-792
32. Kingston, D. G. (2000) Recent advances in the chemistry of taxol J. Nat. Prod. 63, 726-734
33. Zhu, Q., Guo, Z., Huang, N., Wang, M., and Chu, F. (1997) Comparative molecular field analysis of a series of paclitaxel analogues J. Med. Chem. 40, 4319-4328
34. Lataste, H., Senilh, V., Wright, M., Guénard, D., and Potier, P. (1984) Relationships between the structures of taxol and baccatine III derivatives and their in vitro action on the disassembly of mammalian brain and Physarum amoebal microtubules Proc. Natl. Acad. Sci. U.S.A. 81, 4090-4094
35. Ueda, Y., Wong, H., Matiskella, J. D., Mikkilineni, A. B., Farina, V., Fairchild, C., Rose, W. C., Mamber, S. W., Long, B. H., Kerns, E. H., Casazza, A. M., and Vyas, D. M. (1994) Synthesis and antitumor evaluation of 2′-oxycarbonylpaclitaxels (paclitaxel-2′-carbonates) Bioorg. Med. Chem. Lett. 4, 1861-1864
36. Kingston, D. G. I. (1994) Taxol: The chemistry and structure-activity relationships of a novel anticancer agent Trends Biotechnol. 12, 222-227
37. Paradis, R. and Page, M. (1998) New active paclitaxel amino acids derivatives with improved water solubility Anticancer Res. 18, 2711-2716
38. Nicolaou, K. C., Riemer, C., Kerr, M. A., Rideout, D., and Wrasidlo, W. (1993) Design, synthesis and biological activity of protaxols Nature 364, 464-466
39. Zhao, Z., Kingston, D. G. I., and Crosswell, A. R. (1991) Modified taxols, 6. preparation of water-soluble prodrugs of taxol J. Nat. Prod. 54, 1607-1611
40. Rose, W. C., Clark, J. L., Lee, F. Y., and Casazza, A. M. (1997) Preclinical antitumor activity of water-soluble paclitaxel derivatives Cancer Chemother. Pharmacol. 39, 486-492
41. Ueda, Y., Mikkilineni, A. B., Knipe, J. O., Rose, W. C., Casazza, A. M., and Vyas, D. M. (1993) Novel water-soluble phosphate prodrugs of Taxol(R) possessing in-vivo antitumor-activity Bioorg. Med. Chem. Lett. 3, 1761-1766
42. deBont, D. B. A., Leenders, R. G. G., Haisma, H. J., vanderMeulenMuileman, I., and Scheeren, H. W. (1997) Synthesis and biological activity of beta-glucuronyl carbamate-based prodrugs of paclitaxel as potential candidates for ADEPT Bioorg. Med. Chem. 5, 405-414
43. Takahashi, T., Tsukamoto, H., and Yamada, H. (1998) Design and synthesis of a water-soluble taxol analogue: Taxol-sialyl conjugate Bioorg. Med. Chem. Lett. 8, 113-116
44. Lee, H., Lee, K., and Park, T. G. (2008) Hyaluronic acid-paclitaxel conjugate micelles: Synthesis, characterization, and antitumor activity Bioconjugate Chem. 19, 1319-1325
45. Wang, Y., Xin, D., Liu, K., Zhu, M., and Xiang, J. (2009) Heparin-paclitaxel conjugates as drug delivery system: Synthesis, self-assembly property, drug release, and antitumor activity Bioconjugate Chem. 20, 2214-2221
46. Wang, S. D., Zhelev, N. Z., Duff, S., and Fischer, P. M. (2006) Synthesis and biological activity of conjugates between paclitaxel and the cell delivery vector penetratin Bioorg. Med. Chem. Lett. 16, 2628-2631
47. Li, C., Yu, D. F., Newman, R. A., Cabral, F., Stephens, L. C., Hunter, N., Milas, L., and Wallace, S. (1998) Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate Cancer Res. 58, 2404-2409
48. Papas, S., Akoumianaki, T., Kalogiros, C., Hadjiarapoglou, L., Theodoropoulos, P. A., and Tsikaris, V. (2007) Synthesis and antitumor activity of peptide-paclitaxel conjugates J. Pept. Sci. 13, 662-671
49. Kirschberg, T. A., VanDeusen, C. L., Rothbard, J. B., Yang, M., and Wender, P. A. (2003) Arginine-based molecular transporters: The synthesis and chemical evaluation of releasable taxol-transporter conjugates Org. Lett. 5, 3459-3462
50. Chen, X. Y., Plasencia, C., Hou, Y. P., and Neamati, N. (2005) Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery J. Med. Chem. 48, 1098-1106
51. Safavy, A., Raisch, K. P., Khazaeli, M. B., Buchsbaum, D. J., and Bonner, J. A. (1999) Taxane derivatives for targeted therapy of cancer: Design and synthesis of a soluble paclitaxel-peptide conjugate with enhanced antitumor activity Clin. Cancer Res. 5, 3820s-3820s
52. Sohn, J. S., Jin, J. I., Hess, M., and Jo, B. W. (2010) Polymer prodrug approaches applied to paclitaxel Polym. Chem. 1, 778-792
53. Greenwald, R. B., Gilbert, C. W., Pendri, A., Conover, C. D., Xia, J., and Martinez, A. (1996) Drug delivery systems: Water soluble taxol 2′-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness J. Med. Chem. 39, 424-431
54. Etrych, T., Sirova, M., Starovoytova, L., Rihova, B., and Ulbrich, K. (2010) HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release Mol. Pharmaceutics 7, 1015-1026
55. Hostetler, K. Y. and Sridhar, N. C. Prodrugs for Oral Administration Containing Taxol Covalently Bound to a Phospholipid. U.S. Patent 5,484,809, January 16, 1996.
56. Ansell, S. Lipophilic Drug Derivatives for Use in Liposomes. U.S. Patent 5,534,499, July 9, 1996.
57. Perkins, W. R., Ahmad, I., Li, X. G., Hirsh, D. J., Masters, G. R., Fecko, C. J., Lee, J. K., Ali, S., Nguyen, J., Schupsky, J., Herbert, C., Janoff, A. S., and Mayhew, E. (2000) Novel therapeutic nano-particles (lipocores): Trapping poorly water soluble compounds Int. J. Pharm. 200, 27-39
58. Stevens, P. J., Sekido, M., and Lee, R. J. (2004) A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug Pharm. Res. 21, 2153-2157
59. Ali, S., Ahmad, I., Peters, A., Masters, G., Minchey, S., Janoff, A., and Mayhew, E. (2001) Hydrolyzable hydrophobic taxanes: Synthesis and anti-cancer activities Anti-Cancer Drugs 12, 117-128
60. Bradley, M. O., Webb, N. L., Anthony, F. H., Devanesan, P., Witman, P. A., Hemamalini, S., Chander, M. C., Baker, S. D., He, L. F., Horwitz, S. B., and Swindell, C. S. (2001) Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel Clin. Cancer Res. 7, 3229-3238
61. Ke, X. Y., Zhao, B. J., Zhao, X., Wang, Y., Huang, Y., Chen, X. M., Zhao, B. X., Zhao, S. S., Zhang, X., and Zhang, Q. (2010) The therapeutic efficacy of conjugated linoleic acid-paclitaxel on glioma in the rat Biomaterials 31, 5855-5864
62. Lee, J. W., Lu, J. Y., Low, P. S., and Fuchs, P. L. (2002) Synthesis and evaluation of taxol-folic acid conjugates as targeted antineoplastics Bioorg. Med. Chem. 10, 2397-2414
63. Bedikian, A. Y., DeConti, R. C., Conry, R., Agarwala, S., Papadopoulos, N., Kim, K. B., and Ernstoff, M. (2011) Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma Ann. Oncol. 22, 787-793
64. Jones, R., Hawkins, R., Eatock, M., Ferry, D., Eskens, F. L. M., Wilke, H., and Evans, T. R. J. (2008) A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma Cancer Chemother. Pharmacol. 61, 435-441
65. Reddy, L. H. and Couvreur, P. (2010) Lipid-Based Anticancer Prodrugs, in Macromolecular Anticancer Therapeutics, Springer.
66. Couvreur, P., Stella, B., Reddy, L. H., Hillaireau, H., Dubernet, C., Desmaele, D., Lepetre-Mouelhi, S., Rocco, F., Dereuddre-Bosquet, N., Clayette, P., Rosilio, V., Marsaud, V., Renoir, J. M., and Cattel, L. (2006) Squalenoyl nanomedicines as potential therapeutics Nano Lett. 6, 2544-2548
67. Desmaele, D., Gref, R., and Couvreur, P. (2012) Squalenoylation: A generic platform for nanoparticular drug delivery J. Controlled Release 161, 609-618
68. Raouane, M., Desmaele, D., Gilbert-Sirieix, M., Gueutin, C., Zouhiri, F., Bourgaux, C., Lepeltier, E., Gref, R., Ben Salah, R., Clayman, G., Massaad-Massade, L., and Couvreur, P. (2011) Synthesis, characterization, and in vivo delivery of siRNA-squalene nanoparticles targeting fusion oncogene in papillary thyroid carcinoma J. Med. Chem. 54, 4067-4076
69. Dosio, F., Reddy, L. H., Ferrero, A., Stella, B., Cattel, L., and Couvreur, P. (2010) Novel nanoassemblies composed of squalenoyl-paclitaxel derivatives: Synthesis, characterization, and biological evaluation Bioconjugate Chem. 21, 1349-1361
70. Caron, J., Maksimenko, A., Wack, S., Lepeltier, E., Bourgaux, C., Morvan, E., Leblanc, K., Couvreur, P., and Desmaele, D. (2013) Improving the antitumor activity of squalenoyl-paclitaxel conjugate nanoassemblies by manipulating the linker between paclitaxel and squalene Adv. Healthcare Mater. 2, 172-185
71. Maksimenko, A., Mougin, J., Mura, S., Sliwinski, E., Lepeltier, E., Bourgaux, C., Lepetre, S., Zouhiri, F., Desmaele, D., and Couvreur, P. (2013) Polyisoprenoyl gemcitabine conjugates self assemble as nanoparticles, useful for cancer therapy Cancer Lett. 334, 346-353
72. Harrisson, S., Nicolas, J., Maksimenko, A., Bui, D. T., Mougin, J., and Couvreur, P. (2013) Nanoparticles with in vivo anticancer activity from polymer prodrug amphiphiles prepared by living radical polymerization Angew. Chem., Int. Ed. 52, 1678-1682
73. Menon, S., Sinha-Mahapatra, D., and Herndon, J. W. (2007) Synthesis of phenanthrene derivatives through the net [5 + 5]-cycloaddition of prenylated carbene complexes with 2-alkynylbenzaldehyde derivatives Tetrahedron 63, 8788-8793
74. Bekkara-Aounallah, F., Gref, R., Othman, M., Reddy, L. H., Pili, B., Allain, V., Bourgaux, C., Hillaireau, H., Lepeître-Mouelhi, S., Desmaële, D., Nicolas, J., Chafi, N., and Couvreur, P. (2008) Novel PEGylated nanoassemblies made of self-assembled squalenoyl nucleoside analogues Adv. Funct. Mater. 18, 3715-3725
75. Vittaz, M., Bazile, D., Spenlehauer, G., Verrecchia, T., Veillard, M., Puisieux, F., and Labarre, D. (1996) Effect of PEO surface density on long-circulating PLA-PEO nanoparticles which are very low complement activators Biomaterials 17, 1575-1581
76. Storm, G., Belliot, S. O., Daemen, T., and Lasic, D. D. (1995) Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system Adv. Drug Delivery Rev. 17, 31-48
77. Peracchia, M. T., Fattal, E., Desmaele, D., Besnard, M., Noel, J. P., Gomis, J. M., Appel, M., d'Angelo, J., and Couvreur, P. (1999) Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting J. Controlled Release 60, 121-128
78. Dosio, F., Brusa, P., Crosasso, P., Arpicco, S., and Cattel, L. (1997) Preparation, characterization and properties in vitro and in vivo of a paclitaxel-albumin conjugate J. Controlled Release 47, 293-304
79. Yamamoto, Y., Kawano, I., and Iwase, H. (2011) Nab-paclitaxel for the treatment of breast cancer: Efficacy, safety, and approval Onco Targets Ther. 4, 123-136
80. Aslakson, C. J. and Miller, F. R. (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor Cancer Res. 52, 1399-1405
81. Tao, K., Fang, M., Alroy, J., and Sahagian, G. G. (2008) Imagable 4T1 model for the study of late stage breast cancer BMC Cancer 8, 228-246
82. Miller, F. R. (1983) Tumor subpopulation interactions in metastasis Invasion Metastasis 3, 234-242